Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Impact of Soylent consumption on human gut microbiome composition

ABSTRACT: An interventional Soylent diet increases the Bacteroidetes to Firmicutes ratio in human gut microbiome communities: a randomized controlled trial

PROVIDER: PRJEB21752 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR2031290_1.fastq.gz	Fastqsanger.gz
	ERR2031290_2.fastq.gz	Fastqsanger.gz
	ERR2031300_1.fastq.gz	Fastqsanger.gz
	ERR2031300_2.fastq.gz	Fastqsanger.gz
	ERR2031310_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 544

Similar Datasets

Transcriptional profiling of primary prostate tumor in metastatic hormonesensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED study

Project description:Gene expression study of the ECOG 3805 randomized controlled trial

2022-05-01 | GSE201805 | GEO

Gut microbiota analysis associated with autism spectrum disorders [16S rRNA]

Project description:Here we report 16S rRNA data in gut microbiota of autism spectrum disorders compared with healthy volunteers. A total of 1322 operational taxonomic units (OTUs) were identified in the sequence data. The Bacteroidetes and Firmicutes were both dominated phylum in ausitic subjects and healthy controls. Phylum level analysis showed a clear alteration of the bacterial gut community in ASD characterized by a higher Firmicutes (P < 0.05), Proteobacteria (P < 0.001), and Actinobacteria (P < 0.001) than that in healthy controls. However, Bacteroidetes were significantly decreased in ASD patients (P < 0.001).

2020-09-30 | GSE113690 | GEO

Project description:Randomized controlled trial of molnupiravir SARS-CoV-2

| PRJNA1066240 | ENA

IL-1 inhibition in systemic sclerosis skin.

Project description:IL-1 has been implicated in various fibrotic diseases. This randomized, Placebo-Controlled trial we examine the effect of il1-b inhibition on skin expression. We used microarrays to explore gene expression changes in the Rilonacept clinical trial

2019-09-12 | GSE119939 | GEO

Project description:Changes in the Bacteroidetes:Firmicutes Ratio of the Thanatomicrobiota in Substance Abuse Disorders

| PRJNA779460 | ENA

High-throughput sequencing of plasma microRNA in elderly men fed a high protein diet in relation to the PBMC transcriptome: A 10 week randomized controlled trial

Project description:High-throughput sequencing of plasma microRNA in elderly men fed a high protein diet in relation to the PBMC transcriptome: A 10 week randomized controlled trial

2019-07-01 | GSE111063 | GEO

Expression data from skin biopsies in patients with systemic sclerosis treated with beta-catenin inhibitor (C82) and placebo

Project description:Wnt signaling pathway is thought to have a role in skin fibrosis in Systemic slcerosis. This Randomized, Placebo-Controlled trial examines the effect of beta catenin inhibition on skin expression. We used microarrays to explore gene expression changes in the C82 trial

2018-01-01 | GSE94340 | GEO

Metagenome sequencing of feces of mouse treated D-galactose or not

Project description:D-galactose orally intake ameliorate DNCB-induced atopic dermatitis by modulating microbiota composition and quorum sensing. The increased abundance of bacteroidetes and decreased abundance of firmicutes was confirmed. By D-galactose treatment, Bacteroides population was increased and prevotella, ruminococcus was decreased which is related to atopic dermatitis.

2022-04-29 | E-MTAB-11632 | biostudies-arrayexpress

Activity of afatinib in a window pre-operative EORTC study in patients with squamous cell carcinoma of the head and neck (HNSCC)

Project description:Afatinib is a pan-HER inhibitor that improved progression-free-survival (PFS) in recurrent HNSCC versus methotrexate: median PFS 2.6 versus 1.7 months (LUX H&N 1 trial). This study is a translational research linked to EORTC 90111 afatinib trial, an open-label, randomized, multicenter, phase II window of opportunity trial. Treatment-naïve HNSCC patients selected for primary curative surgery were randomized (5:1 ratio) to receive Afatinib during 14 days (day -15 until day -1) before surgery (day 0) or no treatment. Tumour biopsies, FDG/PET, and MRI were performed at diagnosis and at surgery. The primary end point was metabolic FDG-PET/CT response, defined according to EORTC guidelines.

2019-01-23 | GSE101491 | GEO

Total skin transcriptome modification induced by IL-17A blockade

Project description:We studied psoriasis skin transcriptome modification induced by systemic IL-17A blockade with microarray analyses of total skin as part of a randomized placebo-controlled clinical trial (ClinicalTrial.gov identifier: NCT03131570)

2023-09-04 | GSE226244 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data